FDA Approves MacroGenics Drug Margenza For Breast Cancer With Chemotherapy

Biopharmaceutical company MacroGenics Announced Wednesday FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer following Phase 3 clinical trials. Product launch anticipated in March of 2021